STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...

Switching between infliximab biosimilar SB2 and the reference product ... According to the investigators, “the initial and the reverse switch had no relevant impact on the course of disease ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...

Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CTP43 or Reference Ustekinumab) in Patients with Moderate ...